iBio (NASDAQ:IBIO – Get Free Report) and BioNTech (NASDAQ:BNTX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Volatility and Risk
iBio has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and price targets for iBio and BioNTech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iBio | 1 | 0 | 4 | 4 | 3.22 |
| BioNTech | 1 | 5 | 12 | 1 | 2.68 |
Profitability
This table compares iBio and BioNTech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iBio | N/A | -40.66% | -35.78% |
| BioNTech | -63.54% | -6.86% | -6.00% |
Insider & Institutional Ownership
7.9% of iBio shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 1.5% of iBio shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares iBio and BioNTech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iBio | $100,000.00 | 810.31 | -$33.04 million | ($0.34) | -3.71 |
| BioNTech | $2.65 billion | 9.35 | -$1.29 billion | ($7.83) | -12.52 |
iBio has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.
Summary
iBio beats BioNTech on 8 of the 14 factors compared between the two stocks.
About iBio
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
About BioNTech
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
